Dr. Kohli on the SELECT Trial: Semaglutide Reduces MACE in Obese Patients With Heart Disease

By Payal Kohli, MD, FACC - Last Updated: August 17, 2023

Novo Nordisk recently announced the headline results from the SELECT cardiovascular outcomes trial, which showed that semaglutide, a GLP-1 receptor agonist, reduces major adverse cardiovascular events in overweight or obese adults with cardiovascular disease.

DocWire News Medical Lead Dr. Payal Kohli talked about this landmark study and the impact of the findings on the cardiovascular community.

Post Tags:Cardiology Videos
Latest News

September 22, 2023